Expression of the ACE2 virus entry protein in the nervus terminalis reveals the potential for an alternative route to brain infection in COVID-19

Previous studies suggested that the SARS-CoV-2 virus may gain access to the brain by using a route along the olfactory nerve. However, there is a general consensus that the obligatory virus entry receptor, angiotensin converting enzyme 2 (ACE2), is not expressed in olfactory receptor neurons, and the timing of arrival of the virus in brain targets is inconsistent with a neuronal transfer along olfactory projections. We determined whether nervus terminalis neurons and their peripheral and central projections should be considered as a potential alternative route from the nose to the brain. Nervus terminalis neurons in postnatal mice were double-labeled with antibodies against ACE2 and two nervus terminalis markers, gonadotropin-releasing hormone (GnRH) and choline acetyltransferase (CHAT). We show that a small fraction of CHAT-labeled nervus terminalis neurons, and the large majority of GnRH-labeled nervus terminalis neurons with cell bodies in the region between the olfactory epithelium and the olfactory bulb express ACE2 and cathepsins B and L. Nervus terminalis neurons therefore may provide a direct route for the virus from the nasal epithelium, possibly via innervation of Bowman's glands, to brain targets, including the telencephalon and diencephalon. This possibility needs to be examined in suitable animal models and in human tissues.

Errataetall:

UpdateIn: Front Cell Neurosci. 2021 Jul 05;15:674123. - PMID 34290590

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - year:2021

Enthalten in:

bioRxiv : the preprint server for biology - (2021) vom: 07. Juni

Sprache:

Englisch

Beteiligte Personen:

Bilinska, Katarzyna [VerfasserIn]
von Bartheld, Christopher S [VerfasserIn]
Butowt, Rafal [VerfasserIn]

Links:

Volltext

Themen:

ACE2
Brain infection
COVID-19
Cathepsin
Nervus terminalis
Olfactory system
Preprint
SARS-CoV-2

Anmerkungen:

Date Revised 11.02.2024

published: Electronic

UpdateIn: Front Cell Neurosci. 2021 Jul 05;15:674123. - PMID 34290590

Citation Status PubMed-not-MEDLINE

doi:

10.1101/2021.04.11.439398

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM324348444